Gary Webb MD – Cincinnati Adolescent and Adult Congenital Heart Disease Program, The Heart Institute at Cincinnati Children's Hospital Medical Center
"As the director of the Cincinnati Adult Congenital Heart Disease (ACHD) Program, and former director of the Toronto ACHD Program, and founder and inaugural president of the International Society of Adult Congenital Cardiac Disease, I wish to provide an unsolicited comment on the international status and roles of the Royal Brompton Hospital and its renowned congenital heart disease team.
The strength, commitment and multiple contributions of the institution go back to the 1950s when Dr Paul Wood established some of the key principles for life-long follow-up and treatment of congenital heart disease. His textbook “Diseases of the Heart and Circulation” remains one of the classic publications in the field. The Royal Brompton Team (and in particular Dr Shinebourne and Professors Anderson and Ho) in subsequent years was instrumental in establishing the common language in describing congenital heart defects and the spectrum of disease. Following the legacy of Paul Wood, Dr Rigby and Professor Redington were leaders in describing integrated physiology and its application in the congenital heart disease field. Major advances in surgery also originated from this Institution. Professor Sir Magdi Yacoub practised at the Brompton. Following the closure of the National Heart Hospital, the Royal Brompton Hospital benefited from additional expertise, including my senior colleague Professor Somerville, who has been a national and international advocate for the needs of the patient with ACHD (also called GUCH “Grown-Up Congenital Heart”).
Since Professor Somerville’s retirement, the team has expanded under the academic leadership of Professor Gatzoulis and now consists of five consultant ACHD cardiologists - a clear indication of the commitment of the Trust towards this expanding cardiovascular field.
Furthermore, the Royal Brompton has made additional investment in cardiac imaging (including MRI), ACHD cardiac surgery and more recently in electrophysiology (with magnetic navigation). The clinical results of the ACHD group I understand to be excellent, and the Royal Brompton is one of the national and international referral centers for even the most complex forms of congenital heart disease. The Royal Brompton group’s academic contributions have been equally important: the group has published a remarkable number of high-impact papers, including more than 30 full papers in Circulation; trained more than 80 national and international fellows who now practice ACHD in the UK and overseas; and the members of the Royal Brompton ACHD team are consistently present as keynote speakers at national and international meetings or have served in recent years as visiting professors in some of the most esteemed universities around the world.
In summary, I would consider the Royal Brompton ACHD Group as one of the top three ACHD groups in the world, in terms of its clinical excellence, academic contributions and training and educational opportunities. In my opinion, it has accomplished more in the last decade than any other center in the world.
I understand that there is a national process and review of pediatric cardiac surgical services and that the review represents a threat to the congenital heart services at the Royal Brompton & Harefield NHS Foundation Trust. Such a possible action would be unimaginable for those of us in the international ACHD community, as it would jeopardize a world leader in the field, having an adverse impact on both patient care and the ongoing development of the specialty, not only at national, but also at a global level. There is no doubt, that if paediatric cardiac services are affected and removed from the Royal Brompton, that ACHD care and the Royal Brompton’s national and international leadership would be compromised.
This is, therefore, my plea to reconsider the proposed options, so that this British flagship institution continues uninterrupted its important role towards advancing of the care of all patients with congenital heart disease and improving our understanding and treatment of their condition."